Last $11.00 USD
Change Today -0.10 / -0.90%
Volume 3.6K
ADMA On Other Exchanges
As of 8:10 PM 01/27/15 All times are local (Market data is delayed by at least 15 minutes).

adma biologics inc (ADMA) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/3/14 - $14.00
52 Week Low
04/30/14 - $6.76
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ADMA BIOLOGICS INC (ADMA)

Related News

No related news articles were found.

adma biologics inc (ADMA) Related Businessweek News

No Related Businessweek News Found

adma biologics inc (ADMA) Details

ADMA Biologics, Inc., a late stage biopharmaceutical company, develops, manufactures, and intends to market plasma-based biologics for the treatment and prevention of infectious diseases. Its lead product candidate, RI-002, which is in Phase III clinical trial, is intended for the treatment of primary immune deficiency disease. RI-002 is an injectable immune globulin derived from human plasma enriched with high levels of naturally occurring polyclonal antibodies, as well as high levels of antibodies targeted to respiratory syncytial virus. The company also operates ADMA BioCenters, which are plasma collection centers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.

42 Employees
Last Reported Date: 03/28/14
Founded in 2004

adma biologics inc (ADMA) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: $484.3K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $343.9K
Chief Scientific & Medical Officer and Execut...
Total Annual Compensation: $320.5K
Compensation as of Fiscal Year 2013.

adma biologics inc (ADMA) Key Developments

ADMA Biologics Receives $5 million Tranche from Hercules Technology Growth Capital

ADMA Biologics, Inc. announced that it has received a $5 million tranche from Hercules Technology Growth Capital, Inc. The $5 million was based upon ADMA achieving clinical endpoints of a Phase III clinical study of RI-002 as a treatment for Primary Immunodeficiency Disease (PIDD), under its existing loan and security agreement.

ADMA Biologics, Inc. Announces Positive Phase III Data for Primary Immune Deficiency Disease (PIDD) Patients

ADMA Biologics, Inc. announced its product candidate RI-002 has demonstrated positive Phase III results and successfully achieved its primary endpoint. The Phase III US based clinical study enrolled 59 patients with diagnosed primary immune deficiency disease (PIDD) who received the investigational product, RI-002 for 12 months. While final data from the study will be reported during the first quarter of 2015, preliminary analysis indicates that treatment with RI-002 resulted in no serious bacterial infections (SBI) observed in study subjects during the trial. This is well under the Food and Drug Administration (FDA) requirement of <=1 SBI per patient-year and therefore the trial successfully achieved its primary endpoint. Secondary endpoints include incidence of all infections (serious & non-serious), lost days of work or school, hospitalizations, emergency room visits and antibiotic use among others. Data on these secondary endpoints is expected to be provided during the first quarter of 2015. In this Phase III trial, measurements of key secondary endpoints including trough levels of IgG were made. The pharmacokinetic profile of total IgG was measured and met required criteria. This pharmacokinetic component of Study ADMA-003 was consistent with the requirements for the pharmacokinetic characterization of IVIG as specified in FDA's 2008 Guidance for Industry: Safety, Efficacy, and Pharmacokinetic Studies to Support Marketing of Immune Globulin Intravenous (Human) as Replacement Therapy for Primary Humoral Immunodeficiency. The Company plans to report on additional secondary endpoints when the data is available.

ADMA Biologics, Inc. Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-11-2014 10:20 AM

ADMA Biologics, Inc. Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-11-2014 10:20 AM. Venue: The Crowne Plaza Hotel, New York, New York, United States. Speakers: Adam S. Grossmann, Founder, Chief Executive Officer, President and Director, Brian Lenz, Chief Financial Officer, Principal Accounting Officer and Vice President.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ADMA:US $11.00 USD -0.10

ADMA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ADMA.
View Industry Companies

Industry Analysis


Industry Average

Valuation ADMA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 21.3x
Price/Book 11.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 15.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ADMA BIOLOGICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at